Completed PHASE1 INTERVENTIONAL 5-arm NCT03624959

Drug-drug Interaction Study of Ozanimod With Inhibitor or Inducer of CYP2C8 and/or CYP3A

A Phase 1, Randomized, Parallel-Group, Open-Label Study to Evaluate the Effect of the Modulators of the Cytochrome P450 (CYP) 2C8 and/or 3A on the Single-Dose Pharmacokinetics of Ozanimod and CC112273 in Healthy Adult Subjects

Sponsor: Celgene

Conditions Healthy Volunteer

Interventions Gemfibrozil Itraconazole Ozanimod Rifampin

Updated 9 times since 2018 Last updated: May 28, 2019 Started: Jun 20, 2018 Primary completion: Aug 10, 2018 Completion: Aug 10, 2018

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT03624959, this PHASE1 trial focuses on Healthy Volunteer and remains completed. Sponsored by Celgene, it has been updated 9 times since 2018, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

9 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2019 — Jan 2021 [monthly]

Completed PHASE1

Status: Recruiting → Completed
Feb 2019 — Jun 2019 [monthly]

Recruiting PHASE1

▶ Show 4 earlier versions

Jan 2019 — Feb 2019 [monthly]

Recruiting PHASE1
Dec 2018 — Jan 2019 [monthly]

Recruiting PHASE1
Nov 2018 — Dec 2018 [monthly]

Recruiting PHASE1
Sep 2018 — Nov 2018 [monthly]

Recruiting PHASE1

First recorded

Jun 2018

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Celgene

Data source: Celgene

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Austin, United States